Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The firm presently has a $15.00 target price on the specialty pharmaceutical company’s stock. Zacks Investment Research‘s price target indicates a potential upside of 1.15% from the stock’s previous close.

According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

A number of other research firms have also issued reports on COLL. BidaskClub upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 5th. Cantor Fitzgerald set a $35.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Friday, March 8th. ValuEngine upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, February 28th. SunTrust Banks assumed coverage on Collegium Pharmaceutical in a research report on Tuesday, March 19th. They set a “buy” rating and a $22.00 price objective for the company. Finally, Janney Montgomery Scott assumed coverage on Collegium Pharmaceutical in a research report on Friday, April 12th. They set a “buy” rating and a $29.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Collegium Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $28.00.

NASDAQ:COLL opened at $14.83 on Monday. Collegium Pharmaceutical has a 12-month low of $13.10 and a 12-month high of $28.91. The company has a market cap of $494.91 million, a P/E ratio of -12.46 and a beta of 0.32. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 0.11.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, February 27th. The specialty pharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.65. Collegium Pharmaceutical had a negative return on equity of 41.12% and a negative net margin of 13.95%. The business had revenue of $73.40 million during the quarter, compared to analyst estimates of $72.71 million. During the same quarter in the previous year, the firm posted ($0.54) EPS. The business’s revenue for the quarter was up 579.6% compared to the same quarter last year. Equities analysts expect that Collegium Pharmaceutical will post -0.31 EPS for the current fiscal year.

In other Collegium Pharmaceutical news, Director Michael Thomas Heffernan sold 25,000 shares of Collegium Pharmaceutical stock in a transaction on Friday, February 15th. The stock was sold at an average price of $14.81, for a total transaction of $370,250.00. Following the sale, the director now owns 259,430 shares of the company’s stock, valued at approximately $3,842,158.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 75,000 shares of company stock worth $1,176,750 in the last ninety days. 8.08% of the stock is owned by company insiders.

A number of institutional investors have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System raised its stake in Collegium Pharmaceutical by 4.8% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 14,359 shares of the specialty pharmaceutical company’s stock valued at $247,000 after acquiring an additional 655 shares in the last quarter. Meeder Asset Management Inc. raised its stake in Collegium Pharmaceutical by 644.8% during the 4th quarter. Meeder Asset Management Inc. now owns 3,672 shares of the specialty pharmaceutical company’s stock valued at $62,000 after acquiring an additional 3,179 shares in the last quarter. Bank of America Corp DE raised its stake in Collegium Pharmaceutical by 17.2% during the 4th quarter. Bank of America Corp DE now owns 23,981 shares of the specialty pharmaceutical company’s stock valued at $412,000 after acquiring an additional 3,525 shares in the last quarter. Strs Ohio raised its stake in Collegium Pharmaceutical by 11.5% during the 1st quarter. Strs Ohio now owns 39,800 shares of the specialty pharmaceutical company’s stock valued at $602,000 after acquiring an additional 4,100 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in Collegium Pharmaceutical by 6.2% during the 3rd quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock valued at $1,136,000 after acquiring an additional 4,484 shares in the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Recommended Story: What is a stock buyback?

Get a free copy of the Zacks research report on Collegium Pharmaceutical (COLL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.